Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 7 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Global IVD and CDx Market: Introduction and Overview | 11 | 2 |
| In-vitro and Companion diagnostics | 11 | 1 |
| Overview | 11 | 1 |
| GBI Research Report Guidance | 12 | 1 |
| Global IVD and CDx Market: Market Characterization | 13 | 14 |
| Global IVD and CDx Market, Revenues ($m), 2002 2009 | 13 | 2 |
| Global IVD and CDx Market, Revenue Forecasts ($m), 2009 2016 | 15 | 2 |
| Global IVD and CDx Market, Key Company Shares (%), 2009 | 17 | 1 |
| Global IVD and CDx Market: Key Market Trends | 18 | 1 |
| Entry of Diagnostic Imaging Players Into In Vitro Diagnostics Market has Set the Stage for New Technologies to be Developed by Marrying the Two Disciplines | 18 | 1 |
| Large Number of Private Equity/Venture Capital (PE/VC) Investments and Collaborations in the IVD Sector will Fuel Innovation | 19 | 1 |
| Consolidation of Laboratories across the World | 19 | 1 |
| Global IVD and CDx Market: Key Technology Trends | 20 | 1 |
| Emerging Technologies for Cutting Laboratory Costs | 20 | 1 |
| POCT Technology | 20 | 1 |
| Automation | 20 | 1 |
| New Technologies Improve Speed and Accuracy | 21 | 1 |
| Advanced Technologies Such as Miniaturization of Rapids Tests Expand Use of POCT to Critical Care and Emergency Medicine | 21 | 1 |
| Growth of Molecular Diagnostics is Facilitating Early Disease Detection | 21 | 1 |
| Rising Emphasis on Patient Centric, Personalized Medicine to Accelerate Development of Companion Diagnostics | 21 | 1 |
| Global IVD and CDx Market: Market Drivers | 22 | 1 |
| Economic Market Drivers | 22 | 1 |
| Emerging Countries to Play an Important Role in Driving Growth | 22 | 1 |
| Need to Control Costs at Laboratories to Drive Adoption of New Processes and Instruments | 22 | 1 |
| Retail Testing Services are Going to Have a Positive Impact on the IVD Market, as Accessibility to the Common Man Improves | 23 | 1 |
| Technology Market Drivers | 24 | 1 |
| Growth in New Technologies Such as Molecular Diagnostics and Rapid Tests to Drive IVD Market | 24 | 1 |
| Regulatory Market Drivers | 24 | 1 |
| Emergence of Laws for Patent Protection | 24 | 1 |
| Easing Regulations to Drive Decentralized Testing | 24 | 1 |
| Social Market Drivers | 25 | 1 |
| Paradigm Shift towards Preventive Medicine to Drive Growth in Diagnostics for Early Detection and Screening | 25 | 1 |
| Patient Centric Medicine with Better Informed Consumers Assumes More Significant Role in Managing Their Health | 25 | 1 |
| Ageing Population to Drive Demand for IVD Tests for Monitoring and Disease Detection | 25 | 1 |
| Global IVD and CDx Market: Market Restraints | 25 | 1 |
| Economic Market Restraints | 25 | 1 |
| Healthcare Budget Deficits in the Majority of Developed Nations to Lead to Rationalization of Testing | 25 | 1 |
| Pricing Pressures, Low Levels of Reimbursements, Reimbursement Cuts, and Lack of Monetary Incentives for New Tests to Impede Market Growth | 25 | 1 |
| Local Players for Consumables put Pricing Pressures on International Players in Developing Nations | 26 | 1 |
| Social Market Restraints | 26 | 1 |
| Shortage of Skilled Labor a Major Problem for Laboratories | 26 | 1 |
| Global IVD and CDx Market: Market Category Analysis and Forecasts | 27 | 63 |
| Clinical Chemistry Market: Market Characterization | 27 | 1 |
| Global Clinical Chemistry Market, Revenues ($m), 2002 2009 | 27 | 2 |
| Global Clinical Chemistry Market, Revenue Forecasts ($m), 2009 2016 | 29 | 2 |
| Global Clinical Chemistry Market, Key Company Shares (%), 2009 | 31 | 1 |
| Clinical Chemistry Market: Market Drivers | 32 | 1 |
| The US and the UK Market Segments Are Expected to Drive Growth in the Global Clinical Chemistry Market | 32 | 1 |
| Need for Greater Productivity and Throughput Gains and Need for Cost Saving Will Drive Segments Such as POC, Rapid Tests, and Automated Analyzers | 33 | 1 |
| Need for integration will drive purchases of integrated chemical analyzers | 33 | 1 |
| Ageing population and consequent rise in the incidence of chronic and infectious diseases will continue to drive market growth | 33 | 1 |
| Clinical Chemistry Market: Market Restraints | 33 | 1 |
| Market Maturity is Putting Downward Pricing Pressures on Vendors | 33 | 1 |
| Revised FDA Guidelines and Increased Compliance Expected to Adversely Impact Small Laboratories | 34 | 1 |
| Immuno Chemistry Market: Market Characterization | 35 | 1 |
| Global Immuno Chemistry Market, Revenues ($m), 2002 2009 | 35 | 2 |
| Global Immuno Chemistry Market, Revenue Forecasts ($m), 2009 2016 | 37 | 2 |
| Global Immuno Chemistry Market, Key Company Shares (%), 2009 | 39 | 2 |
| Immuno Chemistry Market: Market Drivers | 41 | 1 |
| The US Immuno Chemistry Market, Followed By Italy Will Drive Growth in Global Immuno Chemistry Market | 41 | 1 |
| Advances in Molecular Biology, Discovery of New Biomarkers and New Applications to Drive Future Growth | 42 | 1 |
| Technological Innovations Such as Miniaturization of Biosensors, Microfluidics and Nanotechnology Leading to Development of New, Innovative Immunodiagnostic Rapid Tests | 42 | 1 |
| Pharmacogenomics and Need for Personalized Testing to Determine Drug Response to Drive Immuno Chemistry Market in the Future | 43 | 1 |
| Increasing Awareness of Early Screening, Detection and Diagnosis Fuelling Growth | 43 | 1 |
| Immuno Chemistry Market: Market Restraints | 43 | 1 |
| Low Reimbursement Rates Hamper the Development and Uptake of New Immunoassays | 43 | 1 |
| Hematology Market: Market Characterization | 44 | 1 |
| Global Hematology Market, Revenues ($m), 2002 2009 | 44 | 2 |
| Global Hematology Market, Revenue Forecasts ($m), 2009 2016 | 46 | 2 |
| Global Hematology Market, Key Company Shares (%), 2009 | 48 | 1 |
| Hematology Market: Market Drivers | 49 | 1 |
| The US, the UK and Italy to Lead Growth in the Global Hematology Market | 49 | 1 |
| Technological Advancements which aid in Miniaturization, Enhanced Menu Options and Improved Throughput Will Drive the Market | 50 | 1 |
| Adoption of Automated Analyzers in Small-to-Medium Laboratories Will Lead to Market Growth | 50 | 1 |
| Hematology Market: Market Restraints | 50 | 1 |
| Intense Competition Puts Downward Pressure on Profit Margins | 50 | 1 |
| Histology and Cytology Market: Market Characterization | 51 | 1 |
| Global Histology and Cytology Market, Revenue ($m), 2002 2009 | 51 | 1 |
| Global Histology and Cytology Market, Revenue Forecasts ($m), 2009 2016 | 52 | 1 |
| Global Histology and Cytology Market, Key Company Shares (%), 2009 | 53 | 1 |
| Histology and Cytology Market: Market Drivers | 54 | 1 |
| The US and Italy Market Segments Will Drive the Market | 54 | 1 |
| Advances in Cell/Tissue Staining, Biopsy in Cancer Detection and Diagnosis and Automation Technology Will Drive Market Growth | 55 | 1 |
| Histology and Cytology Market: Market Restraints | 55 | 1 |
| New Molecular, Non-Invasive Blood Tests Threaten To Cannibalize Market for Detection of Infectious Diseases | 55 | 1 |
| Consolidated Market Creates Entry Barriers for Small Players | 55 | 1 |
| Microbiology Culture Market: Market Characterization | 56 | 1 |
| Global Microbiology Culture Market, Revenues ($m), 2002 2009 | 56 | 2 |
| Global Microbiology Culture Market, Revenue Forecasts ($m), 2009 2016 | 58 | 2 |
| Global Microbiology Culture Market, Key Company Shares (%), 2009 | 60 | 1 |
| Global Microbiology Culture Market: Market Drivers | 61 | 1 |
| The US, Itlay and the UK Market Segments Are Expected To Drive Microbiology Market Growth | 61 | 1 |
| High Prevalence of Infectious Diseases Will Sustain Market Growth in the Future | 62 | 1 |
| Improved Efficiency, Time Savings and Lack of Skilled Labor Will Lead to Increased Adoption of Automation | 62 | 1 |
| Global Microbiology Culture Market: Market Restraints | 62 | 1 |
| Molecular Diagnostics Are Increasingly Replacing the Time-Consuming Process of Bacterial Culture | 62 | 1 |
| Infectious Immunology Market: Market Characterization | 63 | 1 |
| Global Infectious Immunology Market, Revenues ($m), 2002 2009 | 63 | 1 |
| Global Infectious Immunology Market, Revenue Forecasts ($m), 2009 2016 | 64 | 1 |
| Global Infectious Immunology Market, Key Company Shares (%), 2009 | 65 | 1 |
| Global Infectious Immunology Market: Market Drivers | 66 | 1 |
| The US and Italy Hold High Potential for Market Growth | 66 | 1 |
| Emergence of Highly Infectious Mutant Strains Of Pathogens Will Drive the Demand for Appropriate Diagnostics to Contain the Spread of These Agents | 67 | 1 |
| New Cases of Humans Infected With Animal Pathogens Will Lead to High Demand for Diagnostic Tests | 67 | 1 |
| Global Infectious Immunology Market: Market Restraints | 67 | 1 |
| Reimbursement Systems that do not Provide Incentives to New Tests Will Hold Back Market Growth | 67 | 1 |
| Genetic Testing Market: Market Characterization | 68 | 1 |
| Global Genetic Testing Market, Revenues ($m), 2002 2009 | 68 | 1 |
| Global Genetic Testing Market, Revenue Forecasts ($m), 2009 2016 | 69 | 1 |
| Global Genetic Testing Market, Key Company Shares (%), 2009 | 70 | 1 |
| Global Genetic Testing Market: Market Drivers | 71 | 1 |
| Rapid Adoption of Genetic Testing for Screening Genetic Disorders and High Risk Patients to Drive the Market | 71 | 1 |
| Advances in Genetics and Proteomics, and Better Understanding of Underlying Genetic Causes of Diseases Will Drive Test Volumes through New Tests | 72 | 1 |
| Rising Awareness Driven by Direct to Consumer Marketing is Going to Drive the Market in the Future | 72 | 1 |
| Pharmacogenomic Testing To Play a Significant Role in Driving the Genetics Testing Market | 72 | 1 |
| Global Genetic Testing Market: Market Restraints | 72 | 1 |
| Prohibitive Costs for Genetic Tests Likely to Temper High Growth in Demand in the Future | 72 | 1 |
| Lack of Standardization of Genetic Tests Creates Doubts about the Validity of Tests | 73 | 1 |
| Global Companion Diagnostics Market: Market Characterization | 73 | 1 |
| Introduction | 73 | 3 |
| Selected Companion Diagnostic Assays/Kits | 76 | 1 |
| AmpliChip CYP450 | 76 | 1 |
| Oncotype Dx | 76 | 1 |
| MammaPrint | 76 | 1 |
| Theros Breast Cancer Index | 76 | 1 |
| HercepTest | 76 | 1 |
| DakoCytomation EGFR PharmDx | 77 | 1 |
| PGx Predict:Rituximab | 77 | 1 |
| PhyzioType PIMS | 77 | 1 |
| THEROS CancerTYPE ID | 77 | 1 |
| CupPrint | 78 | 1 |
| AlloMap gene profile | 78 | 1 |
| Target GI Test | 78 | 1 |
| HER2 FISH pharmDx Kit | 78 | 1 |
| PGx Predict:Rituximab | 78 | 1 |
| eQ-PCR LC Warfarin Genotyping kit | 79 | 1 |
| Applications of Companion Diagnostics | 79 | 1 |
| Optimization of Therapy | 79 | 1 |
| Increased Safety and Accuracy | 79 | 1 |
| Rescue drugs failing in the market | 80 | 1 |
| Preventive rather than Curative Approach | 80 | 1 |
| Reduce Time, Cost and Failure Rate of Clinical Trials | 81 | 1 |
| Global Companion Diagnostics Market, Revenue Forecasts ($m), 2009 2016 | 81 | 1 |
| Global Companion Diagnostics Market, Oncology, Revenue Forecasts ($m), 2009-2016 | 82 | 2 |
| Global Companion Diagnostics Market, Infectious Diseases, Revenue Forecasts ($m), 2009-2016 | 84 | 2 |
| Global Companion Diagnostics Market, Cardiovascular Diseases, Revenue Forecasts ($m), 2009-2016 | 86 | 1 |
| Global Companion Diagnostics Market, 2010 | 87 | 1 |
| Global Companion Diagnostics Market: Market Drivers | 88 | 1 |
| Increase in healthcare costs | 88 | 1 |
| Patient Compliance | 88 | 1 |
| Better Regulatory Norms and Validation Procedures | 88 | 1 |
| Global Companion Diagnostics Market: Market Restraints | 88 | 1 |
| Payer Reimbursement Issues | 88 | 1 |
| Ethical Issues | 89 | 1 |
| Lack of Proper Medical Information Technology | 89 | 1 |
| Awareness Gap Lack of Physician Education and Awareness about Novel Technologies | 89 | 1 |
| Global IVD and CDx Market: Country Analysis and Forecasts | 90 | 30 |
| Global IVD Market: Geographic Trends Analysis | 90 | 1 |
| Market Characterization, the US, 2002 2016 | 91 | 1 |
| The US IVD and CDx Market, Revenues ($m), 2002 2009 | 91 | 2 |
| The US IVD and CDx Market, Revenues ($m), 2009 2016 | 93 | 1 |
| The US IVD and CDx Market, Market Drivers | 94 | 1 |
| Ageing Population and Technological Innovation to Drive Testing Volumes | 94 | 1 |
| Point Of Care and Satellite Laboratory Testing in Non-Traditional, Ambulatory Settings to Gain Increased Focus in the Future | 94 | 1 |
| The US IVD and CDx Market, Market Restraints | 94 | 1 |
| Heightened Regulatory Oversight on Personalized Testing Such as Direct to Consumer Genetic Testing to Hamper Growth of Private Players | 94 | 1 |
| Market Characterization, Europe, 2002 2016 | 95 | 1 |
| The UK IVD and CDx Market | 95 | 1 |
| The UK IVD and CDx Market, Revenues ($m), 2009 2016 | 96 | 2 |
| Germany IVD and CDx Market, Revenues ($m), 2002 2009 | 98 | 2 |
| Germany IVD and CDx Market, Revenues ($m), 2009 2016 | 100 | 2 |
| France IVD and CDx Market, Revenues ($m), 2002 2009 | 102 | 2 |
| France IVD and CDx Market, Revenues ($m), 2009 2016 | 104 | 2 |
| Italy IVD and CDx Market, Revenues ($m), 2002 2009 | 106 | 2 |
| Italy IVD and CDx Market, Revenues ($m), 2009 2016 | 108 | 2 |
| Spain IVD and CDx Market, Revenues ($m), 2002 2009 | 110 | 2 |
| Spain IVD and CDx Market, Revenues ($m), 2009 2016 | 112 | 1 |
| Europe IVD and CDx Market, Market Drivers | 113 | 1 |
| Ageing population to drive growth due to increase in routine testing | 113 | 1 |
| Increasing Surveillance for Hospital Acquired Infections to Drive Screening Kits | 113 | 1 |
| Consolidation of Laboratories to Create Opportunities in the Laboratory Automation for Managing Pre-Analytical and Post-Analytical Phases | 113 | 1 |
| Europe IVD and CDx Market, Market Restraints | 114 | 1 |
| Healthcare Budget Deficits in the Majority of European Markets to Continue to Lead to Rationalization of Testing | 114 | 1 |
| Purchase Organizations will Leverage their Position to Negotiate Low Cost Contracts, Leading to Thinning Margins | 114 | 1 |
| Market Characterization, Japan, 2002 2016 | 115 | 1 |
| Japan IVD and CDx Market, Revenues ($m), 2002 2009 | 115 | 2 |
| Japan IVD and CDx Market, Revenues ($m), 2009 2016 | 117 | 1 |
| Japan IVD and CDx Market, Market Drivers | 118 | 1 |
| Ageing Population Will Drive Growth in Developed Countries Such as Japan and Australia, While Population Growth Will Drive Emerging Economies | 118 | 1 |
| Increased Technology Adoption will be a Uniform Trend Driving the Sales of IVD Instruments in the Future | 118 | 1 |
| Japan IVD and CDx Market, Market Restraints | 119 | 1 |
| Laboratory Consolidation to Put a Further Squeeze on the IVD Margins in Japan and Australia | 119 | 1 |
| Local Players Give Tough Competition to International Players by Offering Cheap Products | 119 | 1 |
| Global IVD and CDx Market: Strategic Competitive Assessment | 120 | 24 |
| Key Market Participants | 120 | 1 |
| F. Hoffmann-La Roche Ltd | 120 | 1 |
| Company Overview | 120 | 1 |
| Deals Landscape | 121 | 1 |
| Pipeline Product Portfolio | 122 | 2 |
| Siemens Medical Solutions USA, Inc. | 124 | 1 |
| Company Overview | 124 | 1 |
| Deals Landscape | 124 | 1 |
| Pipeline Product Portfolio | 125 | 1 |
| Abbott Laboratories | 126 | 1 |
| Company Overview | 126 | 1 |
| Deals Landscape | 127 | 1 |
| Pipeline Product Portfolio | 128 | 1 |
| Beckman Coulter, Inc. | 129 | 1 |
| Company Overview | 129 | 1 |
| Deals Landscape | 130 | 1 |
| Pipeline Product Portfolio | 131 | 1 |
| bioMerieux Sa | 132 | 1 |
| Company Overview | 132 | 1 |
| Deals Landscape | 133 | 1 |
| Pipeline Product Portfolio | 134 | 1 |
| Ortho-Clinical Diagnostics | 134 | 1 |
| Company Overview | 134 | 1 |
| Deals Landscape | 134 | 1 |
| Pipeline Product Portfolio | 135 | 1 |
| Becton, Dickinson and Company | 135 | 1 |
| Company Overview | 135 | 1 |
| Deals Landscape | 136 | 1 |
| Pipeline Product Portfolio | 136 | 1 |
| Bio-Rad Laboratories, Inc. | 137 | 1 |
| Company Overview | 137 | 1 |
| Deals Landscape | 137 | 1 |
| Roche Diagnostics | 137 | 1 |
| Overview | 137 | 1 |
| Deals Landscape | 138 | 1 |
| Pipeline | 139 | 1 |
| Epigenomics AG | 139 | 1 |
| Overview | 139 | 1 |
| Deals Landscape | 140 | 1 |
| Pipeline | 140 | 1 |
| Qiagen N.V | 140 | 1 |
| Overview | 140 | 1 |
| Deals Landscape | 141 | 1 |
| Pipeline | 141 | 1 |
| Dako Denmark A/S | 141 | 1 |
| Overview | 141 | 1 |
| Deals Landscape | 142 | 1 |
| Pipeline | 142 | 1 |
| Celera Corporation | 142 | 1 |
| Overview | 142 | 1 |
| Deals Landscape | 143 | 1 |
| Pipeline | 143 | 1 |
| Global IVD and CDx Market: Product Pipeline Analysis | 144 | 11 |